

Michael E Wechsler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8858858/publications.pdf>

Version: 2024-02-01

172
papers

15,442
citations

19636

61
h-index

18115

120
g-index

177
all docs

177
docs citations

177
times ranked

11052
citing authors

#	ARTICLE	IF	CITATIONS
1	Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. <i>Lancet Respiratory Medicine</i> , 2015, 3, 355-366.	5.2	937
2	Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. <i>New England Journal of Medicine</i> , 2017, 376, 1921-1932.	13.9	682
3	Effectiveness and Safety of Bronchial Thermoplasty in the Treatment of Severe Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 116-124.	2.5	650
4	Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 372-381.e3.	1.5	598
5	Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. <i>Lancet, The</i> , 2004, 364, 1505-1512.	6.3	592
6	Tiotropium Bromide Step-Up Therapy for Adults with Uncontrolled Asthma. <i>New England Journal of Medicine</i> , 2010, 363, 1715-1726.	13.9	467
7	Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. <i>New England Journal of Medicine</i> , 2021, 384, 1800-1809.	13.9	435
8	Smoking Affects Response to Inhaled Corticosteroids or Leukotriene Receptor Antagonists in Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 175, 783-790.	2.5	382
9	Eosinophilic granulomatosis with polyangiitis (Churgâ€“Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. <i>European Journal of Internal Medicine</i> , 2015, 26, 545-553.	1.0	371
10	Daily versus As-Needed Corticosteroids for Mild Persistent Asthma. <i>New England Journal of Medicine</i> , 2005, 352, 1519-1528.	13.9	363
11	Approaches to the treatment of hypereosinophilic syndromes: A workshop summary report. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 117, 1292-1302.	1.5	328
12	Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. <i>Human Molecular Genetics</i> , 2004, 13, 1353-1359.	1.4	315
13	Active Albuterol or Placebo, Sham Acupuncture, or No Intervention in Asthma. <i>New England Journal of Medicine</i> , 2011, 365, 119-126.	13.9	312
14	Î² ₂ -Adrenergic Receptor Polymorphisms and Response to Salmeterol. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 519-526.	2.5	293
15	Pulmonary Infiltrates, Eosinophilia, and Cardiomyopathy Following Corticosteroid Withdrawal in Patients With Asthma Receiving Zafirlukast. <i>JAMA - Journal of the American Medical Association</i> , 1998, 279, 455.	3.8	290
16	Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 1295-1302.e3.	1.5	288
17	What is asthmaâ€“COPD overlap syndrome? Towards a consensus definition from a round table discussion. <i>European Respiratory Journal</i> , 2016, 48, 664-673.	3.1	287
18	Churg-Strauss Syndrome in Patients Receiving Montelukast as Treatment for Asthma. <i>Chest</i> , 2000, 117, 708-713.	0.4	279

#	ARTICLE	IF	CITATIONS
19	Refining the definition of hypereosinophilic syndrome. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 126, 45-49.	1.5	273
20	Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, 1336-1343.	1.5	265
21	Effect of Vitamin D ₃ on Asthma Treatment Failures in Adults With Symptomatic Asthma and Lower Vitamin D Levels. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2083.	3.8	236
22	Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 63-75.	1.5	222
23	Effect of Î²2-adrenergic receptor polymorphism on response to longacting Î²2 agonist in asthma (LARGE) Tj ETQq1 1 0.784314 rgBT /Ov 1754-1764.	6.3	213
24	Asthma: pathogenesis and novel drugs for treatment. <i>BMJ, The</i> , 2014, 349, g5517-g5517.	3.0	189
25	Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. <i>New England Journal of Medicine</i> , 2021, 385, 1656-1668.	13.9	183
26	Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids. <i>Journal of Allergy and Clinical Immunology</i> , 2005, 115, 720-727.	1.5	175
27	The Predicting Response to Inhaled Corticosteroid Efficacy (PRICE) trial. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 119, 73-80.	1.5	170
28	Comparison of Physician-, Biomarker-, and Symptom-Based Strategies for Adjustment of Inhaled Corticosteroid Therapy in Adults With Asthma. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 987.	3.8	166
29	Characterization of Severe Asthma Worldwide. <i>Chest</i> , 2020, 157, 790-804.	0.4	165
30	KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma. <i>New England Journal of Medicine</i> , 2017, 376, 1911-1920.	13.9	159
31	Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>Autoimmunity Reviews</i> , 2017, 16, 1-9.	2.5	140
32	Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1299-1312.	5.2	139
33	Churg-Strauss Syndrome in Patients Treated With Omalizumab. <i>Chest</i> , 2009, 136, 507-518.	0.4	133
34	Type 2 and interferon inflammation regulate SARS-CoV-2 entry factor expression in the airway epithelium. <i>Nature Communications</i> , 2020, 11, 5139.	5.8	131
35	Sex and gender in asthma. <i>European Respiratory Review</i> , 2021, 30, 210067.	3.0	130
36	A trial of clarithromycin for the treatment of suboptimally controlled asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 126, 747-753.	1.5	128

#	ARTICLE	IF	CITATIONS
37	Do "placebo responders" exist?. <i>Contemporary Clinical Trials</i> , 2008, 29, 587-595.	0.8	118
38	Body mass index and phenotype in subjects with mild-to-moderate persistent asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 123, 1328-1334.e1.	1.5	117
39	Exhaled Nitric Oxide in Patients with Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000, 162, 2043-2047.	2.5	115
40	Eosinophilic and Noneosinophilic Asthma. <i>Chest</i> , 2021, 160, 814-830.	0.4	109
41	Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. <i>Lancet Respiratory Medicine</i> , 2022, 10, 11-25.	5.2	109
42	Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2018, Volume 13, 335-349.	0.9	108
43	Sedation and analgesia in the intensive care unit: Evaluating the role of dexmedetomidine. <i>American Journal of Health-System Pharmacy</i> , 2007, 64, 37-44.	0.5	103
44	Eosinophils in Health and Disease: A State-of-the-Art Review. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2694-2707.	1.4	103
45	Predictors of response to tiotropium versus salmeterol in asthmatic adults. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 1068-1074.e1.	1.5	100
46	Mometasone or Tiotropium in Mild Asthma with a Low Sputum Eosinophil Level. <i>New England Journal of Medicine</i> , 2019, 380, 2009-2019.	13.9	95
47	Regenerative Metaplastic Clones in COPD Lung Drive Inflammation and Fibrosis. <i>Cell</i> , 2020, 181, 848-864.e18.	13.5	94
48	Bacterial biogeography of adult airways in atopic asthma. <i>Microbiome</i> , 2018, 6, 104.	4.9	93
49	Novel targeted therapies for eosinophilic disorders. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 563-571.	1.5	90
50	Exhaled breath condensate eicosanoid levels associate with asthma and its severity. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 547-553.	1.5	89
51	Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 2170-2177.	1.5	82
52	Benralizumab as a Steroid-Sparing Treatment Option in Eosinophilic Granulomatosis with Polyangiitis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1186-1193.e1.	2.0	82
53	Impact of Race on Asthma Treatment Failures in the Asthma Clinical Research Network. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 1247-1253.	2.5	81
54	Care pathways for the selection of a biologic in severe asthma. <i>European Respiratory Journal</i> , 2017, 50, 1701782.	3.1	79

#	ARTICLE	IF	CITATIONS
55	Leukotriene Modifiers and Churg-Strauss Syndrome. <i>Drug Safety</i> , 1999, 21, 241-251.	1.4	76
56	Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1288-1298.	5.2	75
57	Combination Therapy with a Long-Acting β_2 -Agonist and a Leukotriene Antagonist in Moderate Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 175, 228-234.	2.5	74
58	Defining a Severe Asthma Super-Responder: Findings from a Delphi Process. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3997-4004.	2.0	74
59	Asthma therapies and churg-strauss syndrome. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 109, S1-S19.	1.5	72
60	Asthma in COVID-19 Hospitalizations: An Overestimated Risk Factor?. <i>Annals of the American Thoracic Society</i> , 2020, 17, 1645-1648.	1.5	66
61	Aeroallergen sensitization correlates with PC20 and exhaled nitric oxide in subjects with mild-to-moderate asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 121, 671-677.	1.5	64
62	ALOX5 promoter genotype, asthma severity and LTC ₄ production by eosinophils. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2006, 61, 97-103.	2.7	63
63	Pulmonary Eosinophilic Syndromes. <i>Immunology and Allergy Clinics of North America</i> , 2007, 27, 477-492.	0.7	62
64	Association of a Missense Mutation in the NOS3 Gene with Exhaled Nitric Oxide Levels. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 168, 228-231.	2.5	61
65	Anticholinergic vs Long-Acting β_2 -Agonist in Combination With Inhaled Corticosteroids in Black Adults With Asthma. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1720.	3.8	61
66	Changing Paradigms in the Treatment of Severe Asthma: The Role of Biologic Therapies. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, S1-S14.	2.0	57
67	Asthma drug use and the development of Churg-Strauss syndrome (CSS). <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 620-626.	0.9	56
68	Workshop report from the National Institutes of Health Taskforce on the Research Needs of Eosinophil-Associated Diseases (TREAD). <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 587-596.	1.5	54
69	Managing Asthma in Primary Care: Putting New Guideline Recommendations Into Context. <i>Mayo Clinic Proceedings</i> , 2009, 84, 707-717.	1.4	52
70	Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 126, 696-701.e1.	0.5	51
71	Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study. <i>Lancet Respiratory Medicine</i> , 2022, 10, 650-660.	5.2	51
72	Novel Targeted Therapies for Eosinophil-Associated Diseases and Allergy. <i>Annual Review of Pharmacology and Toxicology</i> , 2015, 55, 633-656.	4.2	47

#	ARTICLE	IF	CITATIONS
73	How Pharmacogenomics Will Play a Role in the Management of Asthma. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 12-18.	2.5	46
74	Distinct associations of sputum and oral microbiota with atopic, immunologic, and clinical features in mild asthma. Journal of Allergy and Clinical Immunology, 2020, 146, 1016-1026.	1.5	46
75	Impact of Age and Sex on Response to Asthma Therapy. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 551-558.	2.5	45
76	Step-Up Therapy in Black Children and Adults with Poorly Controlled Asthma. New England Journal of Medicine, 2019, 381, 1227-1239.	13.9	44
77	SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma. Respiratory Research, 2020, 21, 264.	1.4	43
78	Selecting the right biologic for your patients with severe asthma. Annals of Allergy, Asthma and Immunology, 2018, 121, 406-413.	0.5	41
79	Reliever-Triggered Inhaled Glucocorticoid in Black and Latinx Adults with Asthma. New England Journal of Medicine, 2022, 386, 1505-1518.	13.9	40
80	Race is associated with differences in airway inflammation in patients with asthma. Journal of Allergy and Clinical Immunology, 2017, 140, 257-265.e11.	1.5	39
81	Genetic associations of the response to inhaled corticosteroids in asthma: a systematic review. Clinical and Translational Allergy, 2019, 9, 2.	1.4	39
82	The role of pharmacogenomics in improving the management of asthma. Journal of Allergy and Clinical Immunology, 2010, 125, 295-302.	1.5	38
83	JAK inhibitors for asthma. Journal of Allergy and Clinical Immunology, 2021, 148, 953-963.	1.5	38
84	Vitamin D Supplementation and the Risk of Colds in Patients with Asthma. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 634-641.	2.5	37
85	Inhibiting Interleukin-4 and Interleukin-13 in Difficult-to-Control Asthma. New England Journal of Medicine, 2013, 368, 2511-2513.	13.9	36
86	Loss of Salmeterol Bronchoprotection against Exercise in Relation to ADRB2 Arg16Gly Polymorphism and Exhaled Nitric Oxide. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 1407-1412.	2.5	35
87	Incidence of Churg-Strauss syndrome in asthma drug users: a population-based perspective. Journal of Rheumatology, 2005, 32, 1076-80.	1.0	35
88	Predicting worsening asthma control following the common cold. European Respiratory Journal, 2008, 32, 1548-1554.	3.1	34
89	Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD). Journal of Leukocyte Biology, 2018, 104, 69-83.	1.5	34
90	Trombone Player's Lung. Chest, 2010, 138, 754-756.	0.4	29

#	ARTICLE	IF	CITATIONS
91	The Placebo Effect in Asthma. <i>Current Allergy and Asthma Reports</i> , 2014, 14, 456.	2.4	29
92	International severe asthma registry (ISAR): protocol for a global registry. <i>BMC Medical Research Methodology</i> , 2020, 20, 212.	1.4	29
93	Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 422-432.	2.0	28
94	PrecISE: Precision Medicine in Severe Asthma: An adaptive platform trial with biomarker ascertainment. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 1594-1601.	1.5	27
95	Getting Control of Uncontrolled Asthma. <i>American Journal of Medicine</i> , 2014, 127, 1049-1059.	0.6	26
96	From DREAM to REALITY and beyond: Mepolizumab for the treatment of eosinophil-driven diseases. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 778-797.	2.7	25
97	Managing asthma in primary care: putting new guideline recommendations into context. <i>Mayo Clinic Proceedings</i> , 2009, 84, 707-17.	1.4	25
98	The Precision Interventions for Severe and/or Exacerbation-Prone (PrecISE) Asthma Network: An overview of Network organization, procedures, and interventions. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 488-516.e9.	1.5	24
99	Exacerbation-prone asthma in the context of race and ancestry in Asthma Clinical Research Network trials. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 1524-1533.	1.5	23
100	Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1202-1216.e23.	2.0	22
101	Clinical Outcomes and Health-Care Resource Use Associated With Reslizumab Treatment in Adults With Severe Eosinophilic Asthma in Real-World Practice. <i>Chest</i> , 2021, 159, 1734-1746.	0.4	20
102	Researching asthma across the ages: Insights from the National Heart, Lung, and Blood Institute's Asthma Network. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 27-33.	1.5	19
103	Zafirlukast and Churg-Strauss Syndrome. <i>Chest</i> , 1999, 116, 266-267.	0.4	18
104	New biologics for allergic diseases. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 285-296.	1.3	18
105	Recurrent Panniculitis in a Man With Asthma Receiving Treatment With Leukotriene-Modifying Agents. <i>Mayo Clinic Proceedings</i> , 2000, 75, 643-645.	1.4	17
106	P2X ₇ -Regulated Protection from Exacerbations and Loss of Control Is Independent of Asthma Maintenance Therapy. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 28-33.	2.5	16
107	Effectiveness and Safety of Bronchial Thermoplasty in the Treatment of Severe Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 1565-1567.	2.5	14
108	Vitamin D3 therapy in patients with asthma complicated by sinonasal disease: Secondary analysis of the Vitamin D Add-on Therapy Enhances Corticosteroid Responsiveness in Asthma trial. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 589-592.e2.	1.5	14

#	ARTICLE	IF	CITATIONS
109	A randomized, open-label, pragmatic study to assess reliever-triggered inhaled corticosteroid in African American/Black and Hispanic/Latinx adults with asthma: Design and methods of the PREPARE trial. <i>Contemporary Clinical Trials</i> , 2021, 101, 106246.	0.8	14
110	Managing Asthma in the 21st Century: The Role of Pharmacogenetics. <i>Pediatric Annals</i> , 2006, 35, 660-669.	0.3	14
111	Geography, generalisability, and susceptibility in clinical trials. <i>Lancet Respiratory Medicine</i> , 2021, 9, 330-332.	5.2	12
112	Asthma Phenotyping in Primary Care: Applying the International Severe Asthma Registry Eosinophil Phenotype Algorithm Across All Asthma Severities. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 4353-4370.	2.0	12
113	An International, Retrospective Study of Off-Label Biologic Use in the Treatment of Hypereosinophilic Syndromes. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1217-1228.e3.	2.0	12
114	Pharmacogenetics of treatment with leukotriene modifiers. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2002, 2, 395-401.	1.1	11
115	Cysteinyl leukotriene antagonism inhibits bronchoconstriction in response to hypertonic saline inhalation in asthma. <i>Respiratory Medicine</i> , 2011, 105, 667-673.	1.3	11
116	The precision interventions for severe and/or exacerbation-prone asthma (PreISe) adaptive platform trial: statistical considerations. <i>Journal of Biopharmaceutical Statistics</i> , 2020, 30, 1026-1037.	0.4	11
117	Identification of patients with Churg-Strauss syndrome (CSS) using automated data. <i>Pharmacoepidemiology and Drug Safety</i> , 2004, 13, 661-667.	0.9	10
118	Asthma pharmacogenetics. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2013, 13, 399-409.	1.1	10
119	Pharmacogenetic studies of long-acting beta agonist and inhaled corticosteroid responsiveness in randomised controlled trials of individuals of African descent with asthma. <i>The Lancet Child and Adolescent Health</i> , 2021, 5, 862-872.	2.7	10
120	Churg-Strauss syndrome. <i>Lancet</i> , 1999, 353, 1970.	6.3	9
121	Bronchial Thermoplasty. <i>Chest</i> , 2015, 147, e73-e74.	0.4	9
122	Combating the Eosinophil with Anti-Interleukin-5 Therapy. <i>New England Journal of Medicine</i> , 2008, 358, 1293-1294.	13.9	8
123	Efficacy of Reslizumab Treatment in Exacerbation-Prone Patients with Severe Eosinophilic Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 3434-3442.e4.	2.0	8
124	Adherence to adding inhaled corticosteroids to rescue therapy in a pragmatic trial with adults with asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 124, 487-493.e1.	0.5	8
125	Impaired SARS-CoV-2 mRNA Vaccine Antibody Response in Chronic Medical Conditions. <i>Chest</i> , 2022, 161, 1490-1493.	0.4	8
126	Controversies in Allergy: The Potential Role of Biologics as First-Line Therapy in Eosinophilic Disorders. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1169-1176.	2.0	8

#	ARTICLE	IF	CITATIONS
127	The Adult Respiratory Distress Syndrome after Dextran Infusion as an Antithrombotic Agent in Free TRAM Flap Breast Reconstruction. <i>Plastic and Reconstructive Surgery</i> , 1999, 103, 1706-1708.	0.7	7
128	Vasopressin for vasopressor-dependent septic shock. <i>American Journal of Health-System Pharmacy</i> , 2005, 62, 1931-1936.	0.5	7
129	The effects of an insertion in the 5'UTR of the AMCase on gene expression and pulmonary functions. <i>Respiratory Medicine</i> , 2011, 105, 1160-1169.	1.3	7
130	Vitamin D3 treatment of vitamin D-insufficient asthmatic patients does not alter immune cell function. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 286-289.e9.	1.5	7
131	Pulmonary eosinophilic vasculitis with granulomas and benralizumab in children. <i>Pediatric Pulmonology</i> , 2021, 56, 1789-1792.	1.0	7
132	Difficult-to-Control Asthma Management in Adults. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 378-384.	2.0	7
133	Case 15-2007. <i>New England Journal of Medicine</i> , 2007, 356, 2083-2091.	13.9	6
134	β_2 -adrenergic receptor genotype and response to salmeterol. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 120, 218-219.	1.5	6
135	Bronchial thermoplasty for asthma: A critical review of a new therapy. <i>Allergy and Asthma Proceedings</i> , 2008, 29, 365-370.	1.0	6
136	Reducing asthma attacks in patients with severe asthma: The role of bronchial thermoplasty. <i>Allergy and Asthma Proceedings</i> , 2015, 36, 242-250.	1.0	6
137	Loss of bronchoprotection with ICS plus LABA treatment, β_2 -receptor dynamics, and the effect of alendronate. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 416-425.e7.	1.5	6
138	Biomarkers to Predict Response to Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists in Adolescents and Adults with Mild Persistent Asthma. <i>Annals of the American Thoracic Society</i> , 2022, 19, 372-380.	1.5	6
139	A rational approach to compare and select biologic therapeutics in asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 128, 379-389.	0.5	6
140	Severe Asthma and the Primary Care Provider: Identifying Patients and Coordinating Multidisciplinary Care. <i>American Journal of Medicine</i> , 2017, 130, 1479.	0.6	5
141	LTC4 Production by Eosinophils in Asthmatic Subjects with Alternative Forms of Alox-5 Core Promoter. <i>Advances in Experimental Medicine and Biology</i> , 2003, 525, 11-14.	0.8	5
142	SARS-CoV-2 mRNA Vaccine Antibody Response in Patients with Asthma Receiving Biologic Therapy: A Real-World Analysis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 644-648.	2.5	5
143	The Genetics of Asthma. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2002, 23, 331-338.	0.8	4
144	Using the high-dose corticotropin test to diagnose relative adrenal insufficiency in vasopressor-dependent septic shock. <i>American Journal of Health-System Pharmacy</i> , 2006, 63, 466-471.	0.5	4

#	ARTICLE	IF	CITATIONS
145	Comment on: International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. <i>European Respiratory Journal</i> , 2014, 44, 267-267.	3.1	4
146	Clinical Issues in Severe Asthma. <i>Chest</i> , 2018, 154, 1459-1460.	0.4	4
147	Adapting clinical trial design to maintain meaningful outcomes during a multicenter asthma trial in the precision medicine era. <i>Contemporary Clinical Trials</i> , 2019, 77, 98-103.	0.8	4
148	Eosinophilic granulomatosis with polyangiitis. , 2022, , 177-192.		4
149	LTC4 synthase polymorphism modifies efficacy of botanical seed oil combination in asthma. <i>SpringerPlus</i> , 2014, 3, 661.	1.2	3
150	Churg-Strauss Syndrome. <i>Chest</i> , 2000, 118, 1515-1516.	0.4	2
151	Personalized asthma therapy in blacks—the role of genetic ancestry. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1370-1372.	1.5	2
152	Concern of underdiagnosing asthma—“COPD overlap syndrome if age limit of 40 years for asthma is used. <i>European Respiratory Journal</i> , 2017, 50, 1701120.	3.1	2
153	The asthma Symptom Free Days Questionnaire: how reliable are patient responses?. <i>Journal of Asthma</i> , 2019, 56, 1222-1230.	0.9	2
154	Pharmacogenetic investigation of efficacy response to mepolizumab in eosinophilic granulomatosis with polyangiitis. <i>Rheumatology International</i> , 2020, 40, 1301-1307.	1.5	2
155	Restarting Respiratory Clinical Research in the Era of the Coronavirus Disease 2019 Pandemic. <i>Chest</i> , 2021, 159, 1173-1181.	0.4	2
156	Confronting the Challenges of Severe Asthma. <i>Journal of Family Practice</i> , 2018, 67, S19-S26.	0.2	2
157	Characteristics and outcomes of ambulatory patients with suspected COVID-19 at a respiratory referral center. <i>Respiratory Medicine</i> , 2022, 197, 106832.	1.3	2
158	Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥ 500 cells/ μ L. <i>European Respiratory Journal</i> , 2022, 59, 2102577.	3.1	2
159	Biologic medications in asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 129, 138-139.	0.5	2
160	Pharmacogenomics and Applications to Asthma Management. , 2018, , 97-112.		1
161	Introducing the Severe Asthma Series of Invited Reviews. <i>Chest</i> , 2021, 160, 1151-1152.	0.4	1
162	In Reply—“Are Eosinophils Needed for Normal Health?. <i>Mayo Clinic Proceedings</i> , 2022, 97, 805-807.	1.4	1

#	ARTICLE	IF	CITATIONS
163	ADRB2 Arg16Gly polymorphism in the LARGE trial – Authors' reply. Lancet, The, 2010, 375, 725.	6.3	0
164	Indications for the use of bronchial thermoplasty in severe asthma. South African Medical Journal, 2015, 105, 808.	0.2	0
165	Reply. Journal of Allergy and Clinical Immunology, 2019, 144, 873-874.	1.5	0
166	Predictors of inhaled corticosteroid taper failure in adults with asthma. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1335-1337.e3.	2.0	0
167	Editorial overview: Allergy and hypersensitivity – an introduction from the editors. Current Opinion in Immunology, 2020, 66, vi-viii.	2.4	0
168	<sc>BT</sc> or <sc>MAB</sc>: That is the question!. Respirology, 2020, 25, 1222-1222.	1.3	0
169	Letter from the USA. Respirology, 2020, 25, 221-222.	1.3	0
170	Churg-Strauss Syndrome. , 2008, , 389-394.		0
171	Nonpharmacological interventions for severe asthma: behavioural and interventional approaches. , 2019, , 304-314.		0
172	Omaliuzumab treatment reduces asthma exacerbations regardless of airway bronchodilator reversibility. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 2181-2183.e1.	2.0	0